ASH 2020: Results of a study examining ibrutinib combined with lenalidomide and rituximab for treatment of relapsed MCL.
Home / Resource Library / Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial